Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
06/2003
06/03/2003US6573431 Recombinant preduodenal lipases and polypeptides derivatives produced by plants, processes for obtaining them and their uses
06/03/2003US6573390 Muscle relaxant, hypotensive agent, respiratory system disorders, gastrointestinal disorders, fertility, incontinence, shock, antiinflammatory agents, immunology, bone disorders, antiproliferative agents
06/03/2003US6573287 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
06/03/2003US6573278 Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
06/03/2003US6573273 Urea substituted imidazoquinolines
06/03/2003US6573259 Inhibitors of interleukin-1β converting enzyme
06/03/2003US6573253 Methods for the administration of amifostine and related compounds
06/03/2003US6573100 DNA vectors without a selection marker gene
06/03/2003US6573066 FtsH from Staphylococcus aureus
06/03/2003US6572858 Uses for anti-malarial therapeutic agents
06/03/2003US6572842 Preparation for dental treatment
06/03/2003CA2273446C Piperidones
05/2003
05/30/2003WO2003044172A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003WO2003044023A1 The use of anti-histaminics for acute reduction of elevated intracranial pressure
05/30/2003WO2003044021A2 Substituted indolizine-like compounds and methods of use
05/30/2003WO2003044010A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity
05/30/2003WO2003044006A1 Substituted benzopyrans as selective estrogen receptor-beta agonists
05/30/2003WO2003043988A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
05/30/2003WO2003043985A1 Heterocyclic compounds and methods of use
05/30/2003WO2003043982A1 Derivatives of andrimide and moiramide b having antibacterial properties
05/30/2003WO2003043661A1 Preparation compositions containing acid-unstable physiologically acitve compounds and process for producing the same
05/30/2003WO2003043651A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood
05/30/2003WO2003043644A1 Ulcerative-colitis therapeutic agent containing iron salt as active ingredient
05/30/2003WO2003043639A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
05/30/2003WO2003043625A1 2-aryl-propionic acids and pharmaceutical compositions containing them
05/30/2003WO2003043621A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003WO2003043619A1 New use for the treatment of gastroesophageal reflux disease
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003WO2003043604A1 Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043518A2 Methods and products for oral care
05/30/2003WO2003015817A3 Oral immunoglobulin treatment for inflammatory bowel disease
05/30/2003WO2003005998A3 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function
05/30/2003WO2002096363A3 Method for treating fibrotic diseases or other indications
05/30/2003WO2002094187A3 Novel use
05/30/2003WO2002070509A3 Antagonists of mcp-1 function and methods of use thereof
05/30/2003WO2002066040A3 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
05/30/2003WO2002057314A3 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
05/30/2003WO2002036116A9 Tripeptidyl peptidase inhibitors
05/30/2003WO2002034244A3 A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
05/30/2003WO2002016313A3 Integrin receptor inhibitors
05/30/2003WO2001080823A3 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
05/30/2003CA2467752A1 Piperidin-2-one derivative compounds and pharmaceutical composition comprising the same as active ingredient
05/30/2003CA2467747A1 Methods and products for oral care
05/30/2003CA2467557A1 Agent which mobilizes multipotential stem cells from tissues to peripheral blood
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003CA2466916A1 New use for the treatment of gastroesophageal reflux disease
05/30/2003CA2466072A1 Substituted indolizine-like compounds and methods of use
05/30/2003CA2464867A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003CA2464542A1 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/29/2003US20030100769 Such s 2-(6-chloro-3-pyridyl)-2-imidazoline which has good affinity for and activate alpha-4-beta-2-nicotinic acetyl-choline receptors; for treatment and prevention of neuro-degenerative disorders (Alzheimer's/Parkinson's disease)
05/29/2003US20030100609 Orally ingesting a quantity of calcium formate sufficient to improve calcium balance or retention
05/29/2003US20030100608 1,4-disubstituted benzo-fused cycloalkyl urea compounds
05/29/2003US20030100603 Administering to the patient subject to a C-reactive protein associated inflammatory condition, an effective amount of a non-alpha-tocopherol enriched tocopherol
05/29/2003US20030100599 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100588 Indole-type inhibitors of p38 kinase
05/29/2003US20030100585 For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )- 3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid
05/29/2003US20030100578 For example, (7R,8R,9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9 -dihydro-pyrano-(2,3-c)imidazo(1,2-a)pyridine
05/29/2003US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease
05/29/2003US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors
05/29/2003US20030100567 Tyrosine kinase inhibitors
05/29/2003US20030100564 Administering 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione and/or metabolite thereof; treating neoplastic diseases, atherosclerosis, restenosis, rheumatoid arthritis, Crohn's disease, diabetic retinopathy, psoriasis, and endometriosis
05/29/2003US20030100563 Such as 7-((3R)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders
05/29/2003US20030100556 Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders
05/29/2003US20030100548 Antiarthritic agents; atherosclerosis and chronic obstructive pulmonary disease treatments
05/29/2003US20030100538 Substituted chalcones as therapeutic compounds
05/29/2003US20030100510 Crystallized structure of type IV collagen NC1 domain hexamer
05/29/2003US20030099747 Thickened oil compositions of edible oil
05/29/2003US20030099730 Nutritional supplement and methods of using it
05/29/2003US20030099718 Nanocrystalline antimicrobial metals (noble metals)formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal sufficient to cause microbiocidal effect; anti-inflammatory activity
05/29/2003US20030099694 Method for the improvement of transport across adaptable semi-permeable barriers
05/29/2003US20030099661 Compositions and methods for the treatment of immune related diseases
05/29/2003US20030099654 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss
05/29/2003US20030099608 Human cytokine receptor
05/28/2003EP1314737A1 Process for producing erythromycin derivative
05/28/2003EP1314721A1 Novel propenohydroxamic acid derivatives
05/28/2003EP1314719A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
05/28/2003EP1314039A2 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type
05/28/2003EP1313875A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer
05/28/2003EP1313857A2 Lipid metabolism molecules
05/28/2003EP1313769A2 Antibodies to human il-1 beta
05/28/2003EP1313740A1 Prodrugs of imidazopyridine derivatives
05/28/2003EP1313739A1 Alkylated imidazopyridine derivatives
05/28/2003EP1313736A2 Condensed pyrazindione derivatives
05/28/2003EP1313733A1 Pyrazolopyridine compound and pharmaceutical use thereof
05/28/2003EP1313718A2 Inhibitors of copper-containing amine oxidases
05/28/2003EP1313715A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
05/28/2003EP1313711A2 Indazole derivatives as jnk inhibitors
05/28/2003EP1313705A1 Gem-substituted alpha v beta 3 integrin antagonists
05/28/2003EP1313699A1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
05/28/2003EP1313697A2 Immunoregulatory compounds, derivatives thereof and their use
05/28/2003EP1313506A1 Immunologic method for the prevention of dental caries
05/28/2003EP1313505A1 Hla binding peptides and their uses
05/28/2003EP1313501A2 Functions for dp214
05/28/2003EP1313499A1 Method for treating the central nervous system by administration of igf structural analogs
1 ... 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 ... 1258